Company intelligence / Profile preview
Scarcell Therapeutics
Paris, Francescarcell.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Scarcell Therapeutics has developed an allogeneic cell therapy product, aeGF, derived from engineered human gingival fibroblasts. Preclinical and veterinary studies have shown safety and efficacy for cartilage regeneration and pain/inflammation reduction. Over 800 companion animals have been treated with up to two years of follow-up. The company’s first-in-human trial for knee osteoarthritis will begin Phase Ib in Europe in June 2025[1][2][3].
- Therapeutic areas
- CardiovascularRheumatologyDermatology
- Modalities
- Allogeneic cell therapy (engineered gingival fibroblasts)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Scarcell Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scarcell Therapeutics.